Applying Therapeutic Strategies to Improve the Quality of Life in Patients with Alzheimer’s Disease

http://academiccme.com/wp-content/uploads/2018/10/iStock-916204062-wpcf_400x400.jpg

Course Information

Therapautic Area: Neurology
Format(s): Webcast
Credit(s): 1.0 AMA PRA Category 1 Credit™ 1.0 CNE contact hours
Activity Dates: November 6, 2018 - November 5, 2019

 

Program Overview

This CME/CNE activity will review recent advances in the application of therapeutic strategies in the improvement of the quality of life in patients with Alzheimer’s disease (AD) as presented at the Florida State Neurology (FSN) 2018 meeting in Orlando, Florida.   The expert faculty will analyze evidence-based data on the current science and emerging therapeutics for the improvement in lifestyle for patients with AD. The faculty will also discuss proper identification of early signs and symptoms in patients with AD as well as analyze the mechanisms of action and clinical trial data of therapeutic options for the treatment of Alzheimer’s disease. Upon completing this activity, learners will gain knowledge on how to use current evidence-based data with the healthcare team to optimize treatment strategies and improve the quality of life in patients with Alzheimer’s disease

Target Audience

Neurologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with Alzheimer’s disease.

Learning Objectives

1. Review the current science of Alzheimer’s disease, including proper identification of early signs and symptoms.
2. Analyze the mechanisms of action and clinical trial data of therapeutic options for the treatment of Alzheimer’s disease.
3. Implement current evidence-based data with the healthcare team to optimize treatment strategies and improve the quality of life in patients with Alzheimer’s disease

Faculty

Isaacson Head ShotRichard S. Isaacson, MD
Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Stuart Isaacson, MD Consultant/Advisor: AbbVie Inc, ACADIA Pharmaceuticals, Inc.; Acorda Therapeutics; Adamas Pharmaceuticals, Inc.; Addex Therapeutics; Allergan, Inc.; Amarantus Bioscience Holdings, Inc; Auspex Pharmaceuticals Inc; Axovant Sciences Ltd.; Biotie Therapies; Britannia Pharmaceuticals Ltd; Cynapsus Therapeutics Inc.; GE Healthcare IMPAX Laboratories, Inc.; Ipsen Kyowa Hakko Co., Ltd.; Lundbeck, Inc.; Medtronic, Inc.; National Parkinson Foundation; Neurocrine Biosciences, Inc.; NeuroDerm Orexo Pfizer Inc; Roche Sunovion Pharmaceuticals Inc; Teva; Neuroscience, Inc.; UCB Pharma, Inc.; US WorldMeds, LLC; XenoPort, Inc.Grant/Research Support: AbbVie Inc.; ACADIA Pharmaceuticals, Inc.; Acorda Therapeutics; Adamas Pharmaceuticals, Inc.; Addex Therapeutics; Allergan, Inc.; Amarantus Bioscience Holdings, Inc.; Auspex Pharmaceuticals Inc; Avid Radiopharmaceuticals, Inc.; Axovant Sciences Ltd.; AZTherapies, Inc.; Biogen; Biotie Therapies; Cynapsus Therapeutics Inc.; Eisai Inc.; Eli Lilly and Company; Enterin; GE Healthcare; IMPAX Laboratories, Inc.; IntecPharma; Ipsen; Kyowa Hakko Co., Ltd.; Lundbeck, Inc. ; Merz Pharmaceuticals; The Michael J. Fox Foundation; Neurocrine Biosciences, Inc.; NeuroDerm; National Institute of Neurological Disorders and Stroke; Orexo; Parkinson Study Group; Pfizer Inc; Pharma Two B; Prothena; Roche; Sanofi; Shire;Sunovion Pharmaceuticals Inc; Teva Neuroscience, Inc.; UCB Pharma, Inc.; US WorldMeds, LLC; XenoPort, Inc.;Speaker’s Bureau: AbbVie Inc.; ACADIA Pharmaceuticals, Inc.; Allergan, Inc.; American Parkinson Disease Association; Britannia Pharmaceuticals Ltd; Cynapsus Therapeutics Inc.; GE Healthcare; GlaxoSmithKline; IMPAX Laboratories, Inc; Ipsen; Lundbeck, Inc; Neurocrine Biosciences, Inc.; National Parkinson Foundation; Teva Neuroscience, Inc.; UCB Pharma, Inc; US WorldMeds, LLC; XenoPort, Inc.

 

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Nicole Brestowski; Chelsey Benedek and Devon Dietzel hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™ 1.0 CNE contact hours. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Celgene Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen MA, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Physicians who receive a grade of 70% or better on the Post-Activity Test             Questions and who complete the Evaluation will receive a CME Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CE Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.

BUTTON


Provided by: AcademicCME-web